Fulgent Genetics, Inc. (NASDAQ:FLGT) CFO Paul Kim Purchases 100,000 Shares of Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) CFO Paul Kim bought 100,000 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were acquired at an average cost of $15.96 per share, for a total transaction of $1,596,000.00. Following the purchase, the chief financial officer now owns 348,282 shares of the company’s stock, valued at approximately $5,558,580.72. The trade was a 40.28 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Fulgent Genetics Stock Performance

Fulgent Genetics stock opened at $16.65 on Thursday. The company has a market capitalization of $509.27 million, a PE ratio of -3.02 and a beta of 1.39. The company has a 50 day moving average price of $17.15 and a 200-day moving average price of $19.30. Fulgent Genetics, Inc. has a fifty-two week low of $14.57 and a fifty-two week high of $25.11.

Analyst Ratings Changes

FLGT has been the subject of a number of recent analyst reports. Piper Sandler dropped their price objective on Fulgent Genetics from $22.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday. StockNews.com raised shares of Fulgent Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday.

Institutional Investors Weigh In On Fulgent Genetics

Institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in shares of Fulgent Genetics by 113.2% during the third quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company’s stock valued at $7,346,000 after buying an additional 179,477 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Fulgent Genetics by 220.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 43,813 shares of the company’s stock valued at $952,000 after purchasing an additional 30,160 shares in the last quarter. State Street Corp lifted its position in shares of Fulgent Genetics by 1.4% in the 3rd quarter. State Street Corp now owns 793,545 shares of the company’s stock worth $17,244,000 after purchasing an additional 10,868 shares during the period. Franklin Resources Inc. bought a new position in shares of Fulgent Genetics during the third quarter valued at approximately $215,000. Finally, Geode Capital Management LLC raised its stake in Fulgent Genetics by 2.7% in the third quarter. Geode Capital Management LLC now owns 502,869 shares of the company’s stock worth $10,930,000 after buying an additional 13,320 shares in the last quarter. 48.06% of the stock is owned by institutional investors.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.